
#MultipleMyeloma #Lymphoma #Haemostasis #Hemophilia unit at @Hemato_Vhebron Fórmate para ayudar y ayuda a formar #buenosmédicos #gestionsanitaria
Barcelona
Joined October 2013
- Tweets715
- Following561
- Followers696
- Likes2.1K
Merche Gironella retweeted
La simulació clínica permet entrenar el maneig de tractaments complexos.
Hem fet una formació per especialistes en hematologia sobre el maneig del pacient amb mieloma múltiple en recaiguda, treballant diferents situacions clíniques i les possibles complicacions dels tractaments.
Merche Gironella retweeted
El Hospital Universitario de Cabueñes, es referente en mieloma y amiloidosis y ahora mejora el diagnosto por los pacientes asturianos. 👇
elcomercio.es/gijon/cabuenes…
Merche Gironella retweeted
Just in: Good news for the myeloma field.
FDA approves teclistamab plus daratumumab (Tec-Dara) combination for myeloma for patients who have had at least one prior line of therapy.
Note: Always use Tec-Dara with monthly IVIG. It’s not optional.
That was fast! And this is unprecedented curve is why.
Merche Gironella retweeted
Review: Extramedullary Multiple Myeloma
onlinelibrary.wiley.com/doi/…
Merche Gironella retweeted
Just out in @NEJM
Majestec-3 trial. Tec-Dara in relapsed myeloma. #ASH25 @End_myeloma @mvmateos
Link: nejm.org/doi/full/10.1056/NE…
More in thread
Merche Gironella retweeted
Ampliamos equipo!
Buscamos hematólogo/a para la Unidad de Ensayos Clínicos @Hemato_Vhebron y otros proyectos científicos🩺🧪
Te apuntas?
(Contactar [email protected])
Merche Gironella retweeted
S'ha fet el curs sobre Mieloma múltiple, centrat en la millora de l’atenció a pacients en recaiguda.
🎯 Objectius: identificar necessitats, avaluar alternatives terapèutiques, detectar toxicitats i prevenir complicacions.
Enhorabona per la feina feta! 👏
Congratulations InmaFernandez for the poster presented at #IMS @Hemato_Vhebron
Merche Gironella retweeted
EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma #mmsm #bmtsm @NatRevClinOncol nature.com/articles/s41571-0…
Merche Gironella retweeted
Andromeda data after 5 years, very reassuring! #EHA2025
Merche Gironella retweeted
CONGRESS | #EHA2025 | Evangelos Terpos @uoaofficial shares the latest update to the EHA-EMN clinical practice guidelines for diagnosis, treatment, and follow-up. Key updates include new guidelines on defining high-risk disease, examinations upon diagnosis, monitoring for SMM, quadruplet regimens in NDMM, targeted therapies in early relapse and sequencing immunotherapies.
Follow our live feed for more updates: loom.ly/hq6n5HU
#mmsm #myeloma #MedEd #MedNews
Merche Gironella retweeted
CONGRESS | #ASCO25 | Suzanne Trudel @pmcancercentre discusses MRD negativity from the DREAMM-8 trial of belamaf plus Pd vs PVd for R/R #MultipleMyeloma. BPd was associated with increased rates of CR-based MRD negativity and MRD negativity was associated with PFS and OS benefits across key subgroups.
Follow our live feed for more updates: loom.ly/s_RkmMc
#mmsm #myeloma #MedicalCongress
Merche Gironella retweeted
Presented at #ASCO25:
In newly diagnosed myeloma, ASCT showed no benefit over chemotherapy in patients without postinduction measurable residual disease, and tandem ASCT was not more effective than single ASCT in those with postinduction MRD. Full MIDAS phase 3 trial results: nej.md/4mkaecR
@ASCO
Merche Gironella retweeted
The On-Body Delivery System redefines care by putting treatment in motion, freeing patients from hospital chairs and giving them the comfort, control, and quality of life they truly deserve! @JCO_ASCO
@TheIACH @COMyCongress
Merche Gironella retweeted
Amazing response rates with trispecific antibody JNJ-5322 in RR MM. N. van de Donk suggest it is as effective as BCMA targeting CART. In fections are still quite high. All patients should get prophylactic IgG replacement. 12 months PFS of 95%. Prophylactic toci significantly reduced CRS, no ICANS seen.
#ASCO25
Merche Gironella retweeted
New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance @iStopMM
@JAMAOnc #mmsm
jamanetwork.com/journals/jam…
Important data coming to support need for new ranges of normal free light chains based on eGFR👇
Merche Gironella retweeted
Macroglobulinemia de Waldeström- Tratamiento
Selección del Esquema según los síntomas del pacientes y los posibles #EAs de los medicamentos
@Fer_martinmoro @HematoRYC en #AgoraH25 #HematoEnRed @sehh_es @SEHHJoven
Merche Gironella retweeted
Brief Report: CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma (CARTITUDE-4 trial) nej.md/4gA6G27
#Hematology
Merche Gironella retweeted
Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24
@thanosdimop @NEJM
Daratumumab significantly prolongs time to active myeloma and overall survival. Proud to be a lead investigator of this trial nejm.org/doi/full/10.1056/NE…
Slides in thread









































